A Game-Changing Approval Sparks a Rally

August 18, 2025, was a big day for Novo Nordisk (NVO). The FDA just handed Wegovy—its blockbuster weight-loss drug—a major new approval: treatment for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions.

This isn’t just another checkbox—it’s a historic first. Wegovy is now the only GLP-1 drug approved for obesity, heart health, AND liver disease, opening doors to Medicare coverage and millions of new patients.

The market loved it:

• U.S. pre-market trading: +4-5%
• Copenhagen shares: +6%

After months of volatility (thanks, Eli Lilly and pricing wars), this could be the catalyst Novo needed to reignite its growth story.

---

The Highs and Lows of Novo’s Rollercoaster Year

Let’s be real—2025 hasn’t been smooth sailing.

• Competition is heating up: Eli Lilly’s Zepbound/Mounjaro is stealing headlines, and cheaper telehealth alternatives are squeezing prices.
• Investor jitters: Everyone’s worried about drug pricing pressures and whether Novo can stay on top.

But here’s the thing—the fundamentals still look strong:

📊 Q1 2025 Financial Snapshot

• Revenue: Up 18% YoY
• Obesity drug sales: Skyrocketing 67%
• Diabetes sales (Ozempic, etc.): Still growing at 13%

💰 Profit Machine

• Net margins over 34% (rare in biotech!)
• ROE above 88% (yes, you read that right)

🌍 Global Reach

• Serving 46 million patients worldwide with diabetes and obesity meds.

So yeah, the stock’s had ups and downs—but this isn’t a company in trouble.

---

What’s Next? Supply, Science, and Smart Moves

Novo isn’t sitting still. Here’s how they’re fighting back:

🔧 Fixing the Supply Crunch

• Bought Catalent’s factories to pump out more Wegovy & Ozempic. (Finally, fewer shortages!)

💊 Pipeline Power

• CagriSema: Next-gen obesity drug on track for 2026 FDA filing.
• Amycretin: Early trials showed ~22% weight loss—could be a game-changer.

💸 Cutting Costs for Patients

• NovoCare Pharmacy: Selling Wegovy for $499/month (half the usual price) for cash-paying Americans.

Analysts think 2025 sales could grow 13-21%, with profits up 19-27%. Some even see the stock hitting $192 by 2030 if the obesity market keeps booming.

---

What Are Investors Saying?

📈 The Bulls:

• “Novo’s margins are insane—35% net profit! They’re in a duopoly with Eli Lilly and still reasonably priced at ~29.5x earnings.”
• *”The weight-loss drug market could hit $77 BILLION by 2030. Novo and Lilly will dominate.”*

⚠️ The Skeptics:

• “Remember when CagriSema’s Phase III flopped last year? The stock tanked. More trial risks ahead.”
• “Pricing pressure and competition could squeeze profits.”

---

The Bottom Line: Should You Bet on Novo?

✅ Reasons to Be Optimistic:
✔️ New FDA approval = More patients, more revenue.
✔️ Best-in-class profitability.
✔️ Pipeline full of potential breakthroughs.
✔️ Obesity market is EXPLODING.

⛔ Risks to Watch:
❌ Eli Lilly isn’t backing down.
❌ Drug pricing battles aren’t going away.
❌ One bad trial could shake confidence.

Final Thought: Novo Nordisk is still a powerhouse, but it’s not without drama. If you believe in the long-term obesity drug boom, this FDA win could be the start of a new rally. But buckle up—it won’t be a smooth ride.

🚀 What’s your take? Bullish or cautious?